Nitrogen Containing Patents (Class 536/18.7)
  • Patent number: 10363690
    Abstract: Method for preparing a chitosan-based porous layer The present invention relates to a method or preparing a chitosan-based, neutralized compressed porous layer, comprising the following steps: —a) a chitosan solution is prepared, —b) said solution is poured into a mold in order to form a layer, —c) the layer obtained in b) is lyophilized so as to obtain a porous layer, —d) said porous layer obtained in c) is compressed, —e) the compressed porous layer obtained in d) is neutralized by means of an NH4OH solution. It also relates to an implant comprising a layer obtained according to such a method.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: July 30, 2019
    Assignee: Sofradim Production
    Inventors: Sébastien Ladet, Sebastien Francois, Julien Claret, Maud Buffin
  • Patent number: 10138518
    Abstract: The present invention relates to an annealing control primer for improving annealing specificity in nucleic acid amplification and its applications to all fields of nucleic acid amplification-involved technology. The present primer comprises (a) a 3?-end portion having a hybridizing nucleotide sequence substantially complementary to a site on a template nucleic acid to hybridize therewith; (b) a 5?-end portion having a pre-selected arbitrary nucleotide sequence; and (c) a regulator portion positioned between said 3?-end portion and said 5?-end portion comprising at least one universal base or non-discriminatory base analog, whereby said regulator portion is capable of regulating an annealing portion of said primer in association with annealing temperature.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: November 27, 2018
    Assignee: SEEGENE, INC.
    Inventor: Jong-Yoon Chun
  • Patent number: 10131717
    Abstract: The present invention relates to topical glycosaminoglycan compositions, particularly hyaluronan compositions, that facilitate the penetration of modified glycosaminoglycans through the skin barrier into the epidermal and dermal layers of the skin, thereby allowing for the dermal administration of a glycosaminoglycan, such as hyaluronan, without requiring an injection. Through their ability to deliver hyaluronan to the epidermal and dermal layers, the present formulations are therefore suitable for use in dermal rejuvenation, enhancement, hyaluronan replenishment and protection therapy. The glycosaminoglycan compositions are also useful as delivery devices to facilitate the dermal and transdermal delivery of cosmetically and pharmaceutically active substances, including pharmaceuticals, polypeptides, proteins and similarly sized biomacromolecules, through the skin barrier.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: November 20, 2018
    Assignee: LONDON HEALTH SCIENCES CENTRE RESEARCH INC.
    Inventor: Eva Turley
  • Patent number: 9751906
    Abstract: The invention relates to the field of carbohydrate chemistry. Provided is a process for the regioselective oxidation of a single secondary hydroxy function of a carbohydrate substrate comprising two or more secondary hydroxy functions, comprising contacting the carbohydrate substrate in a solvent in the presence of a transition metal catalyst complex with an oxidizing agent to yield a mono-oxidized carbohydrate.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: September 5, 2017
    Assignee: Rijksuniversiteit Groningen
    Inventors: Adriaan Jacobus Minnaard, Manuel Jäger, Aditya Lakshmi Narasimha Raju Gottumukkala, Johannes Gerardus de Vries, Andreas Alexander Bastian, Andreas Herrmann
  • Patent number: 9024009
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: May 5, 2015
    Assignees: Janssen Pharmaceutica N.V., Mitsubishi Tanabe Pharma Corporation
    Inventors: Ahmed F. Abdel-Magid, Maureen Chislom, Steven Mehrman, Lorraine Scott, Kenneth M. Wells, Fan Zhang-Plasket, Sumihiro Nomura, Mitsuya Hongu, Yuichi Koga
  • Patent number: 9012412
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 21, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Bao-Ping Zhao
  • Patent number: 8986933
    Abstract: A process for detecting human rhinovirus nucleic acid in a biological sample, includes producing an amplification product by amplifying an human bocavirus nucleotide sequence using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and measuring said amplification product to detect human rhinovirus in said biological sample. Also provided are reagents and methods for detecting and distinguishing human rhinovirus from other viruses. A kit is provided for detecting and quantifying human rhinovirus in a biological sample.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: March 24, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control
    Inventors: Xiaoyan Lu, Dean Erdman
  • Publication number: 20150053114
    Abstract: The present invention relates to a water-soluble pre-reacted binder composition, a method of its manufacture, a use of said pre-reacted binder composition, a method of manufacturing a collection of matter bound by a polymeric binder, a binder solution or dispersion comprising said pre-reacted binder composition, as well as products comprising the pre-reacted binder composition in a cured state.
    Type: Application
    Filed: April 4, 2013
    Publication date: February 26, 2015
    Applicant: KNAUF INSULATION
    Inventors: Carl Hampson, Benedicte Pacorel, Roger Jackson
  • Patent number: 8952141
    Abstract: Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: February 10, 2015
    Assignee: Lipoxen Technologies Incorporated
    Inventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
  • Patent number: 8927497
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 6, 2015
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Patent number: 8901103
    Abstract: This invention provides a method of treating a subject suffering from a dermatologic condition, including, inter alia, psoriasis, contact dermatitis, and seboreic dermatitis, the method includes the step of administering to a subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, in an amount effective to treat the subject suffering from a dermatologic condition.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: December 2, 2014
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventor: Saul Yedgar
  • Publication number: 20140323416
    Abstract: The aspects of the present disclosure are directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient. In particular, to 5-methyldihydromorphone prodrug compounds described in general Formula I and II and the use of the compounds for treating pain associated with a variety of chronic human disorders including for example neuropathic pain and pain associated with cancer, surgeries or injuries.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 30, 2014
    Inventors: Anthony MARFAT, Peter CORNELIUS, Robert VOLKMANN, Panayiotis ZAGOURAS, Frederick Raymond NELSON, Anton Franz Joseph FLIRI
  • Patent number: 8865879
    Abstract: The present invention pertains to chitosan beads consisting of chitosan cross-linked with citrate ions. The present invention furthermore pertains to a filler comprising such chitosan-citrate beads. In one embodiment of the instant invention the filler is a dermal filler. In one further embodiment of the present invention the dermal filler is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler is for use in the treatment of a medical condition. The filler provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler as claimed herein.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: October 21, 2014
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Kevin Kiehm, Bernhard Hauptmeier, Peter Boderke
  • Patent number: 8865878
    Abstract: This invention provides compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: October 21, 2014
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventor: Saul Yedgar
  • Patent number: 8865681
    Abstract: In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: October 21, 2014
    Assignee: Yissum Research Development Company of the Hebrew Unitersity of Jerusalem
    Inventors: Saul Yedgar, Yuval Cohen
  • Publication number: 20140308272
    Abstract: According to the present invention, treatment of prion protein related diseases, and in particular cancer tumours, is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating binding of a prion protein and/or a prion-like protein to a disease related GAG and/or HSPG.
    Type: Application
    Filed: January 17, 2014
    Publication date: October 16, 2014
    Applicant: Sylvan Pharmaceuticals Pty, Ltd.
    Inventors: John Fergus McEwan, David Cullis-Hill, Martin Lyndale Windsor
  • Publication number: 20140303363
    Abstract: The invention relates to providing isolactosamine (Gal?1-3GlcNH2, formula 1) and salts thereof in the form of either anomer or mixture thereof, as well as hydrates or solvates of the free base and salts thereof. The synthesis of isolactosamine and its use in the synthesis of lacto-N-biose containing oligosaccharides are also disclosed.
    Type: Application
    Filed: December 7, 2012
    Publication date: October 9, 2014
    Inventors: Markus Hederos, Christian Risinger, Julien Boutet, Gyula Dekany
  • Publication number: 20140303096
    Abstract: The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 9, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Dania Birte REICHE, Laura JOHNSTON, Nicole MOHREN
  • Patent number: 8853171
    Abstract: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: October 7, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas Butler, Aesop Cho, Choung U. Kim, Jay P. Parrish, Oliver L. Saunders, Lijun Zhang
  • Patent number: 8828968
    Abstract: A nanoparticle of glucidamin derived from organism for treating tumor and preparation method thereof, wherein the viscosity-average molecular weight of glucidamin is in the range of 1×103-9×105, and the amount of free amino groups in the glucidamin is in the range of 50%-100% based on the total amino groups. The preparation method of the nanoparticle comprises steps listed below: (1) adding the glucidamin possessing one or more molecular weight into thin acid solution at 20-60° C. to form saccharan solution, wherein the content of saccharan in solution is in the range of 0.1%-5% by weight; (2) adjusting the pH of the solution to 6-9 in order to form emulsion of microparticle; (3) separating the microparticle from the emulsion, dried at low temperature to obtain the nanoparticle of glucidamin for treating tumor. The nano-class glucidamin can enhance their activity against tumor.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: September 9, 2014
    Assignee: Ningbo Puai Bioengineering Co., Ltd.
    Inventor: Zirong Xu
  • Publication number: 20140243283
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    Type: Application
    Filed: December 18, 2013
    Publication date: August 28, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Yeeman K. Ramtohul, Sanjoy Kumar Das, Caroline Cadilhac, Thumkunta Jagadeeswar Reddy, Louis Vaillancourt, Michel Gallant, Bingcan Liu, Evelyne Dietrich, Frederic Vallee, Julien Martel, Carl Poisson
  • Publication number: 20140228554
    Abstract: A method for the synthesis of a fucooligosaccharide glycosides by reacting a fucosyl donor with H-A-R1 or a salt thereof, wherein A and R1 are as defined herein, under the catalysis of an enzyme capable of transferring fucose is provided. The fucooligosaccharid glycoside compounds, or derivatives thereof, their use in the manufacture of human milk oligosaccharides, and a method of manufacture of human milk oligosaccharides, are also provided.
    Type: Application
    Filed: March 19, 2012
    Publication date: August 14, 2014
    Applicant: Glycom A/S
    Inventors: Elise Champion, Gyula Dekany, Markus Hederos, Karoly Agoston
  • Patent number: 8802840
    Abstract: The invention relates to the use of bicyclic nucleosides and nucleotides based on formula (II) for the treatment of infectious diseases, and in particular, viral infections.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: August 12, 2014
    Assignee: Biota Scientific Management Pty Ltd.
    Inventors: Paula Francom, Roland Henry Nearn, Alistair George Draffan, John Nicholas Lambert, Silas Bond
  • Publication number: 20140220081
    Abstract: The present invention relates to novel galactose derivatives of general formula (I) and their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses.
    Type: Application
    Filed: February 18, 2014
    Publication date: August 7, 2014
    Applicant: L'OREAL
    Inventors: Nathalie PINEAU, Maria Dalko
  • Patent number: 8796434
    Abstract: ?-Lactosamine hydrochloride, substantially free of ?-lactosamine hydrochloride; a method of preparing ?-lactosamine hydrochloride monohydrate from an anomeric mixture of lactosamine hydrochloride, including: preparing a solution including the anomeric mixture of lactosamine hydrochloride, water and at least one water-miscible organic solvent at a temperature of 0-100° C., and cooling the solution to cause crystallization of ?-lactosamine hydrochloride monohydrate; a method of preparing anhydrous ?-lactosamine hydrochloride; and use of ?-lactosamine hydrochloride as a food supplement or intermediate in synthesis.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: August 5, 2014
    Assignee: Glycom A/S
    Inventors: Gyula Dekany, Károly Ágoston, István Bajza, Marie Bøjstrup, Ignacio Fegueroa Pérez, Lars Kröger, Christoph H. Röhrig
  • Patent number: 8785621
    Abstract: A malleable compound according to the invention for use as a disinfectant comprises water, 25 to 40% by weight of a solvent component comprising low-molecular, water-miscible alcohols, 1 to 10% by weight of an active bactericidal component, 3 to 6% by weight hydroxypropylated polygalactomannan with an etherification level of between 0.3 and 1.5 and 0.1 to 0.5% by weight boracic acid or an equivalent amount of boron ions.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: July 22, 2014
    Assignee: Joker AG
    Inventors: Meinrad Flury, Rene H. Dietrich
  • Patent number: 8754064
    Abstract: The present invention relates to methods and nutritional compositions for stimulating the immune system, particularly in subjects with an impaired immune system such as 5 infants, said method comprising administering a composition comprising sheep milk and/or short chain oligosaccharides.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: June 17, 2014
    Assignee: N.V. Nutricia
    Inventors: Laura M'Rabet, Antonie Van Baalen, Bernd Stahl, Arjan Paul Vos, Thomas Hubertus Martinus Snoeren
  • Publication number: 20140154200
    Abstract: The present invention relates to a non-cellulosic polysaccharide derivative: i) having a mean average molecular weight (Mw) from about 100,000 g/mol, preferably from about 150,000 g/mol and more preferably from about 200,000 g/mole to about 2,000,000 g/mol, preferably to about 1,800,000 g/mol and more preferably to about 1,400,000 g/mole; and ii) containing at least one cationic group, with a cationic degree of substitution (DScat.)extraction, from about 0.20 to about 0.30.
    Type: Application
    Filed: July 20, 2012
    Publication date: June 5, 2014
    Applicant: RHODIA OPERATIONS
    Inventors: Gilda Lizarraga, Delphine Mechineau, Dominique Lemos, Caroline Mabille
  • Patent number: 8735557
    Abstract: Derivatives of PSAs are synthesized, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: May 27, 2014
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
  • Patent number: 8722633
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: May 13, 2014
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark Gary Bock
  • Patent number: 8691957
    Abstract: The present invention is provides a crosslinked hyaluronan powder excellent in swellability in water and a method for simply producing the same. A method for producing the swellable crosslinked hyaluronan powder is characterized by comprising mixing a crosslinking agent with a hyaluronan powder in a state dispersed in a liquid medium containing a monovalent alcohol having 1 to 4 carbon atoms and a solubility of the hyaluronan powder of less than 0.1 g/L to cause a crosslinking reaction. Also, the swellable crosslinked hyaluronan powder produced by the method has a swelling ratio in water of 500% or more.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: April 8, 2014
    Assignee: Shiseido Company, Ltd.
    Inventor: Tetsunori Matsumoto
  • Patent number: 8691793
    Abstract: Described herein are compounds such as macromolecules that have been modified in order to facilitate crosslinking and methods of making and using thereof.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: April 8, 2014
    Assignee: University of Utah Research Foundation
    Inventors: Glenn D. Prestwich, Xiao Zheng Shu, Yanchun Liu
  • Patent number: 8691971
    Abstract: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: April 8, 2014
    Inventor: Scott G. Petersen
  • Patent number: 8685929
    Abstract: This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: April 1, 2014
    Assignee: The Regents of the University of California
    Inventors: Donna G. Albertson, Daniel Pinkel, Colin Collins, Joe W. Gray, Bauke Ylstra
  • Publication number: 20140086846
    Abstract: A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): wherein R1, R2, R3, R7, R8, R?1, R?2, R?3, R7? and R8? are selected form hydrogen, a protected C1-C3 hydroxyalkyl group, or a C1-C3 alkyl group; R4, R?4 are selected from a hydrogen, a hydroxyl, a protected hydroxyl group, a protected C1-C3 hydroxyalkyl group, a C1-C3 alkyl group; n is an integer between 0 and 4; R5, R?5 are selected from a hydrogen, a protecting group comprising C1-C30 aliphatic radicals, C3-C30 cycloaliphatic radicals, C2-C30 aromatic radicals, m is an integer between 1 and 10; at least one of R7 and R?7 is acidic groups or protected acidic groups; Y comprises a protein or peptide moiety, a particle, a micelle, a liposome, an organic molecule, oligomer, polymer or a hydrophilic moiety.
    Type: Application
    Filed: September 26, 2012
    Publication date: March 27, 2014
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Brian James Grimmond, Michael James Rishel, Jeannette Christine Roberts
  • Patent number: 8664196
    Abstract: The present invention provides a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark-like chondroitin sulphate, having a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates. The invention also relates to a process for the preparation of said shark-like chondroitin sulphate affording substantially higher productivities and better reproducibility of product quality. The shark-like chondroitin sulphate of the invention shows a high molecular mass and its in vitro biological and anti-inflammatory effectiveness has been shown to be comparable to that of natural products making this polysaccharide potentially useful as a drug in pharmaceutical preparations and nutraceuticals.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 4, 2014
    Assignee: Gnosis S.p.A.
    Inventors: Ermanno Valoti, Niccolò Miraglia, Davide Bianchi, Marco Valetti, Paola Bazza
  • Patent number: 8653049
    Abstract: The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R3 and R8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: February 18, 2014
    Assignees: Imuthes Limited, Institute of Organic Chemistry and Biochemistry AV CR, V.V.I., Vyzkumny USTAV Veterinarniho Lekarstvi, V.V.I.
    Inventors: Karsten Hipler, Andrew Miller, Jaroslav Turanek, Miroslav Ledvina
  • Publication number: 20140046051
    Abstract: A compound of the formula (1) wherein R1 is a group removable by hydrogenolysis, and wherein R2 is OH or R2 is —NHR3 wherein R3 is a group removable by hydrogenolysis. The compound can be made from fructose by a Heyns-rearrangement. The compound can be used then to make free D-mannosamine or its salts, D-mannosamine building blocks and mannosamine containing oligo- or polysaccharides, N-acetyl-D-mannosamine and its hydrates and solvates, neuraminic acid derivatives, and viral neuraminidase inhibitors.
    Type: Application
    Filed: April 11, 2012
    Publication date: February 13, 2014
    Applicant: GLYCOM A/S
    Inventors: Ioannis Vrasidas, Gyula Dekany, Ågnes Jánosi, Markus Hederos, Christoph Röhrig
  • Patent number: 8637436
    Abstract: A biosensor array, system and method for affinity based assays that are able to simultaneously obtain high quality measurements of the binding characteristics of multiple analytes, and that are able to determine the amounts of those analytes in solution. The invention also provides a fully integrated bioarray for detecting real-time characteristics of affinity based assays.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: January 28, 2014
    Assignee: California Institute of Technology
    Inventor: Arjang Hassibi
  • Publication number: 20140024137
    Abstract: Small molecule fluorescent probes for established drug targets such as nucleic acids including DNA and RNA has been developed and disclosed herein. These nucleic acid probes bind to multiple DNA and RNA structures, and to sites crucial for nucleic acid function, such as DNA and RNA major grooves. Displacement of the probes by other binders such as small molecule compounds and/or proteins illicits a fluorescence change in the probe that once detected and analyzed provide binding information of these other binders of interest. Similarly, changes in fluorescence upon binding of the probes to nucleic acid have been applied to screen nucleic acid of different sequence and conformation. The nucleic acid probes and method of uses disclosed herein are advantageously suitable for high-through put screening of libraries of small molecule compounds, proteins, and nucleic acids.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 23, 2014
    Inventors: Dev P. Arya, Frank Anderson Norris
  • Patent number: 8633303
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: January 21, 2014
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
  • Patent number: 8629266
    Abstract: Starch-based dextrin adhesive additives and methods of preparation are described. Adhesives containing the additive exhibit antimicrobial properties and increased water solubility. The additive contains at least one sugar unit, at least one polyphenol side chain, and at least one Frechet-type poly(aryl ether)dendron.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 14, 2014
    Assignee: Empire Technology Development LLC
    Inventor: Glen Leon Brizius
  • Patent number: 8614195
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventor: Gregory Raymond Bebernitz
  • Publication number: 20130324464
    Abstract: Disclosed are an aryl glycoside compound as represented by formula I or formular I?, a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 5, 2013
    Applicants: SHANGHAI CHEMPARTNER CO., LTD, SHANGHAI YINGLI SCIENCE AND TECHNOLOGY CO., LTD
    Inventors: Zusheng Xu, Su Qian
  • Publication number: 20130281395
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: March 22, 2013
    Publication date: October 24, 2013
    Inventor: University of Pittsburgh - of the Commonwealth System of Higher Education
  • Patent number: 8563702
    Abstract: There are provided composite fibers of alginate and chitosan. Also provided are fiber materials methods of producing composite fibers or films and composite films. In one embodiment there is provided a composite fiber of alginate and chitosan suitable for use in wound management products, wherein chitosan polymer is bonded to alginate polymer along the length of the fiber.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: October 22, 2013
    Assignee: The University of Bolton Education Corporation
    Inventors: Mohsen Miraftab, Gillian Mary Smart
  • Patent number: 8557968
    Abstract: The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: October 15, 2013
    Assignee: Sanofi
    Inventors: Philippe Duchaussoy, Jean Pascal Herault, Jean Marc Herbert, Maurice Petitou, Pierre Savi
  • Patent number: 8557782
    Abstract: Glucopyranosyl-substituted benzonitrile derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: October 15, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Frank Himmelsbach, Peter Eickelmann, Achim Sauer, Leo Thomas
  • Patent number: 8551958
    Abstract: Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group, which have the general structural formula given below (I) where A is: aspirin, diflunisal, benorylate, ibufenac, diclofenac, indomethacin, sulindac, ketorolac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, mefenamic acid, meclof enamic acid, flufenamic acid, niflumic acid, and where in the ester group R can be a sugar (amongst which aldose, or ketose pentose, or esose selected from a group of D- and L-enantioiuers of ribose, glucose, galactose, mannose, arabinose, xilose, allose, altrose, gulose, idose and talose and substituted derivatives thereof, such as glucosamine, galactosamine, N-acetyl glucosamine, N-acetyl galactosamine, N-acetyl ribosamine), a disaccharide, a trisaccharide or an oligosaccharide.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 8, 2013
    Assignees: Stewart Italia Srl
    Inventors: Maria Grazia Rimoli, Antonio Calignano, Rosario Cuomo, Gianpiero Boatto, Enrico Abignente, Daniela Melisi, Annalisa Curcio, Elvira Luongo, Giovanna La Rana, Oscar Sasso, Giovanni Sarnelli, Roberto Russo, Maria Nieddu, Carla Cirillo, Salvatore De Lucia
  • Patent number: RE44778
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: February 25, 2014
    Assignee: Glycomimetics, Inc.
    Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst